Anti-cytokine therapies in T1D: Concepts and strategies
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Anti-cytokine therapies in T1D : Concepts and strategies. / Nepom, Gerald T; Ehlers, Mario; Mandrup-Poulsen, Thomas.
I: Clinical Immunology, Bind 149, Nr. 3 Part A, 12.2013, s. 279-85.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Anti-cytokine therapies in T1D
T2 - Concepts and strategies
AU - Nepom, Gerald T
AU - Ehlers, Mario
AU - Mandrup-Poulsen, Thomas
N1 - Copyright © 2013 Elsevier Inc. All rights reserved.
PY - 2013/12
Y1 - 2013/12
N2 - Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several autoimmune disorders. Several of these cytokines are directly implicated in the pathogenesis of type 1 diabetes, suggesting opportunities for design of clinical trials in type 1 diabetes that incorporate selective cytokine blockade as a component of preventative or interventional immunotherapy. The rationale and status of inhibitory therapy directed against IL-1, TNF, IL-12, IL-23, and IL-6 are discussed, towards a goal of using cytokine inhibition as a therapeutic platform to establish an in vivo milieu suitable for modulating the immune response in T1D.
AB - Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several autoimmune disorders. Several of these cytokines are directly implicated in the pathogenesis of type 1 diabetes, suggesting opportunities for design of clinical trials in type 1 diabetes that incorporate selective cytokine blockade as a component of preventative or interventional immunotherapy. The rationale and status of inhibitory therapy directed against IL-1, TNF, IL-12, IL-23, and IL-6 are discussed, towards a goal of using cytokine inhibition as a therapeutic platform to establish an in vivo milieu suitable for modulating the immune response in T1D.
KW - Antibodies, Monoclonal
KW - Clinical Trials as Topic
KW - Diabetes Mellitus, Type 1
KW - Humans
KW - Hypoglycemic Agents
KW - Immunotherapy
KW - Interleukin-1
KW - Interleukin-12
KW - Interleukin-23
KW - Interleukin-6
KW - T-Lymphocytes, Regulatory
KW - Tumor Necrosis Factor-alpha
U2 - 10.1016/j.clim.2013.02.003
DO - 10.1016/j.clim.2013.02.003
M3 - Journal article
C2 - 23510726
VL - 149
SP - 279
EP - 285
JO - Clinical Immunology
JF - Clinical Immunology
SN - 1521-6616
IS - 3 Part A
ER -
ID: 113810511